Ligand Pharmaceuticals (LGND) Presents At Barclays Global Healthcare Conference - Slideshow

Financial Performance and Guidance - Ligand reported 2019 revenues of $120 million[4] - 2019 revenue includes $41.8 million from royalties, $31.5 million from material sales, and $47.0 million from contract payments[6] - The company anticipates double-digit growth across all three revenue segments in 2020[7] - 2020 revenue guidance is $133 million, with a 91% gross margin and adjusted EPS of $3.62[8] - Ligand has $1 billion of cash available for M&A, share repurchase, and capital return[8] Technologies and Portfolio - Ligand's Captisol technology has generated over $350 million in revenue since its acquisition in 2011[9] - The company has over 200 fully-funded partnered programs with over 120 different partners[10] - Ligand anticipates more than 40 clinical and regulatory events and potential for more than 8 product approvals over the next 3 years[10] - Ligand acquired Icagen for $15 million cash at close, plus an earnout of 15% of milestones and royalties, capped at $25 million[14] OmniAb Technology - Ligand has received $114 million in payments related to OmniAb[9] - The number of antibodies in clinical development has more than quadrupled since 2008[31]